Deutsche Bank AG Makes New Investment in Monte Rosa Therapeutics, Inc. $GLUE

Deutsche Bank AG bought a new position in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 75,061 shares of the company’s stock, valued at approximately $1,816,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. ProShare Advisors LLC increased its stake in shares of Monte Rosa Therapeutics by 11.8% during the fourth quarter. ProShare Advisors LLC now owns 11,374 shares of the company’s stock worth $178,000 after purchasing an additional 1,199 shares during the period. MetLife Investment Management LLC grew its holdings in Monte Rosa Therapeutics by 7.5% in the 4th quarter. MetLife Investment Management LLC now owns 26,187 shares of the company’s stock valued at $411,000 after buying an additional 1,831 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in Monte Rosa Therapeutics by 2.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 119,836 shares of the company’s stock worth $540,000 after buying an additional 2,529 shares during the period. SG Americas Securities LLC increased its position in Monte Rosa Therapeutics by 18.5% during the 1st quarter. SG Americas Securities LLC now owns 20,468 shares of the company’s stock worth $337,000 after buying an additional 3,189 shares during the period. Finally, Lazard Asset Management LLC lifted its holdings in shares of Monte Rosa Therapeutics by 42.9% during the second quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock worth $48,000 after buying an additional 3,262 shares in the last quarter. Institutional investors and hedge funds own 79.96% of the company’s stock.

Insider Buying and Selling

In other news, Director Anthony M. Manning sold 10,000 shares of the company’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $23.11, for a total value of $231,100.00. Following the sale, the director directly owned 10,000 shares of the company’s stock, valued at approximately $231,100. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Sharon Townson sold 6,000 shares of the stock in a transaction on Monday, July 6th. The stock was sold at an average price of $23.31, for a total transaction of $139,860.00. Following the sale, the insider owned 67,845 shares of the company’s stock, valued at approximately $1,581,466.95. This trade represents a 8.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 79,603 shares of company stock valued at $1,725,081 in the last ninety days. Insiders own 6.40% of the company’s stock.

Monte Rosa Therapeutics Price Performance

Monte Rosa Therapeutics stock opened at $13.38 on Friday. The business has a 50 day moving average of $19.72 and a 200-day moving average of $18.63. Monte Rosa Therapeutics, Inc. has a 1 year low of $4.60 and a 1 year high of $25.77. The company has a market capitalization of $1.14 billion, a P/E ratio of -7.60 and a beta of 1.59.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The business had revenue of $8.97 million during the quarter, compared to analyst estimates of $12.91 million. Monte Rosa Therapeutics had a negative net margin of 560.85% and a negative return on equity of 43.31%. Equities analysts anticipate that Monte Rosa Therapeutics, Inc. will post -1.32 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on GLUE. Wedbush lowered their target price on shares of Monte Rosa Therapeutics from $37.00 to $27.00 and set an “outperform” rating on the stock in a report on Monday, August 3rd. Guggenheim reissued a “buy” rating and set a $28.00 price target on shares of Monte Rosa Therapeutics in a research report on Tuesday. Zacks Research upgraded Monte Rosa Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. TD Cowen raised Monte Rosa Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Finally, JPMorgan Chase & Co. cut their target price on Monte Rosa Therapeutics from $31.00 to $27.00 and set an “overweight” rating for the company in a research report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Monte Rosa Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $28.50.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.